PLEASE JOIN THE HBS ALUMNI ANGELS OF NEW YORK AND THE HBS HEALTHCARE ALUMNI ASSOCIATION FOR A NIGHT OF INVESTOR INSIGHTS, NETWORKING, AND STARTUP PRESENTATIONS!
HBSHAA Members- please purchase tickets at this link.
5:30-6:00 pm Registration
6:00-6:45 pm Healthcare Investor Panel, Moderated by Todd Davis, Founder, RoyaltyRx Capital LLC, HBS 1997
Sander Duncan, Partner, Lifeforce Capital
Brenton Fargnoli, Partner, AlleyCorp
Barbara Schilberg, CEO, BioAdvance
Adam Fine, General Partner & CEO, Windham Ventures
6:45-7:30 pm Entrepreneur Pitches
Twice – Direct to consumer toothpaste
Palvella Therapeutics – Developing pathogenetically targeted therapies
Proclaim – transforms complicated healthcare workflows for providers and patients into seamless voice and AI-assisted interactions.
The Versi Group – a pharmaceutical company developing treatments for chronic conditions
Wave Drowning Detection – swimmer tracking system that determines risk of drowning
7:30-8:00 pm Networking + Reception
Julian Levine, Twice Co-Founder and CEO
Julian Levine applies nearly a decade of business strategy acumen and visionary entrepreneurship to his role as Co-Founder and CEO of Twice. Following graduation from Cornell University, he immersed himself in the world of finance, leading due diligence for high-profile M&A’s and advising consumer companies on financial strategy. Starting in 2014, Julian began working as a Senior Associate at Stripes Group where he invested in small to mid-stage businesses in consumer, tech, and healthcare, identifying investment opportunities, shepherding entrepreneurs, and developing a keen business sense. Here, Julian was armed with firsthand experience and knowledge to make Twice a true success. In 2015, Julian embarked on a charitable mission to Eleuthera, Bahamas with GLO Good Foundation and singer-songwriter Lenny Kravitz’s Let Love Rule Foundation. On this journey, he witnessed how life changing oral care could be for a community in need. This is where Julian experienced a personal revelation and decided to go global with a mission to make oral care available for everyone, around the world. In 2018, Julian teamed up to co-found Twice alongside his brother Cody and Lenny Kravitz. In his free time, Julian enjoys a good workout, a great book, or a long bike ride with his friends and family.
Cody Levine, Twice Co-Founder & Chief Brand Officer
As an award-winning marketing executive, Cody Levine built his career specializing in crafting and communicating compelling brand stories with emotional resonances. However, he shared his most powerful and poignant story yet by co-founding Twice alongside his brother Julian. Upon graduation from Cornell University, the New York native launched his career at worldwide advertising agency network BBDO NY. As a digital strategist, his creativity fueled high-profile campaigns for organizations ranging from Visa and Lowe’s to HBO, Snickers, and Autism Speaks. By 2014, he achieved Omnicom’s coveted “Emerging Star” award. Two years later, joined the internal creative agency at Live Nation as a strategy director, striking synergy between music and top brands. He spent 2017 as a senior strategist at cutting-edge firm Giant Spoon, further honing his impressive reputation as a sought-after creative. Along the way, his work helped garner Cannes Lion and Clio awards. Cody first recognized the power of a healthy smile during a trip to Rwanda alongside his father, a world-renowned dentist. In 2015, a volunteer mission in partnership with GLO Good Foundation and singer-songwriter Lenny Kravitz’s Let Love Rule Foundation brought him to Eleuthera, Bahamas where he witnessed an epidemic of poor dental care. After revitalizing an entire community through transformative dentistry, Cody, Julian and Lenny Kravitz, decided to bring this mission worldwide and develop Twice. Twice officially launched in 2018 with the mission to revitalize the industry and unlock the power of the world’s smiles.
Cody lives in New York City and remains an avid cycler, world traveler, and music aficionado.
Eboo Versi, The Versi Group President & Founder
Eboo Versi, MD PhD is the president and founder of the Versi Group.
He has over 30 years of experience as a physician, surgeon, academic, teacher, entrepreneur, investor, and senior executive. He is the inventor of several patents, and owns over thirty more U.S. and international patents under the Versi Group and its licensees. Dr. Versi has served as a pharmaceutical executive at several large (Pfizer, Astellas) and small (Pliva, Mt Cook) companies in a medical capacity culminating as Chief Medical Officer, and head of drug development. Previously, he was the chief of Urogynecology at the Brigham & Women’s Hospital and an Associate Professor at Harvard Medical School. Dr. Versi has published over 100 scientific articles in a variety of fields. He is a member of the Royal College of Obstetricians and Gynecologists and has been Chairman of the Research Committee of the American Urogynecologic Society, Chairman of the Socio-economic Committee of the International Consultation on Incontinence, member of the expert advisory panel in Urogynecology for FIGO and several ad hoc committees for the National Institutes of Health. Dr. Versi received his Masters and Doctorate from Oxford University and Medical Degree from Cambridge University in the UK.
Wes Kaupinen, Palvella President & CEO
Wes Kaupinen has served as president and CEO since Palvella’s inception. Mr. Kaupinen brings more than 15 years of entrepreneurial life sciences experience as an operating executive and early stage investor. Prior to Palvella, Mr. Kaupinen was a senior executive at Insmed Incorporated (NASDAQ: INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, where he served as senior vice president of corporate development and commercialization. While at Insmed, he led the global corporate development and U.S. commercial functions, with key responsibilities including corporate strategy, acquisitions and in-licensing, R&D pipeline strategy, patient advocacy, marketing, and pricing and reimbursement. Previously, Mr. Kaupinen was a principal at Quaker Partners, a life sciences venture capital firm with $700mm under management, where he worked on several public and private venture capital investments in the life sciences space. At Quaker, he was responsible for the recruitment of new senior leadership to Insmed to execute on the company’s rare disease strategy, and he was involved in Quaker’s investments in Horizon Pharma (NASDAQ: HZNP) and Achillion Pharmaceuticals (NASDAQ: ACHN). In addition, he led Quaker’s Series A investments in Intact Vascular (backed by NEA, Quaker, and HIG) and TELA Bio (backed by OrbiMed, Quaker, and Signet), playing a key role in the investor syndication, leadership recruitment, and corporate strategy development for each. Mr. Kaupinen has operating experience at two Johnson & Johnson operating companies, including Cordis Cardiology where he worked on the CYPHER sirolimus-eluting stent, the first drug-eluting stent ever launched which leveraged the multi-modal therapeutic properties of sirolimus to significantly improve outcomes for patients with coronary ischemic disease. Earlier in his career, Mr. Kaupinen was an associate at Apax Partners, a global private equity firm, and an analyst in the Life Sciences Investment Banking Group at Robertson Stephens. Mr. Kaupinen has served as a board director or observer for more than ten companies, including Palvella, Intact Vascular, and TELA Bio. He is currently the chief strategy officer for The Castleman Disease Collaborative Network, a non-profit dedicated to finding a cure for Castleman Disease, a rare autoimmune disease. Mr. Kaupinen earned an M.B.A. from The Wharton School of the University of Pennsylvania where he was the recipient of the William L. Kissick MD Scholarship Award. He holds a B.A. in economics from The University of Virginia.
Elena Helgiu, WAVE Drowning Detection Systems Marketing & Business Development
Elena Helgiu runs marketing and business development at WAVE Drowning Detection Systems. WAVE was created with a mission to end drowning, a leading cause of death in both children and adults.
Levin Brown, Proclaim Founder
D. Levin Brown, MD, MPH (Levin) is the Founder of proclaim, a healthcare technology company that transforms healthcare workflows for providers and patients into seamless, voice and AI-assisted experiences. Levin founded proclaim (previously known as Fleet Health) while in medical school as part of the Harvard iLab Venture Incubation Program and later as a UNC School of Medicine Innovation Fellow. From inception, he established proclaim as a leader in healthcare data governance as the first provider of FHIR integration and platform services in the United States. For the past several years, proclaim has helped customers ranging from academic medical centers to startups to tackle complex data challenges related to interoperability by establishing FHIR and Open Standard data governance, analytic, and prediction systems. Levin brings more than 25 years of experience in Python 3+, Scikit-Learn, Numpy, Linux, and multiple database languages. Levin completed his MD from the UNC School of Medicine and received his Masters in Public Health from Harvard.
Julia Hallisey, Proclaim Director of Strategy and Finance
Julia Hallisey is the Director of Strategy and Finance for proclaim (previously known as Fleet Health). Prior to joining proclaim, Julia worked with early stage companies in health tech, positioning them for profitable and sustained growth, and established and led Investor Relations for a $4 billion global specialty finance company, serving as the primary point of contact for investors and the NYSE. Julia is an accomplished professional experienced working with public companies, institutional investors, family offices, early stage businesses and emerging technologies in investment, operating, and communications roles to develop strategy and drive growth. Julia received a Bachelor of Arts from Smith College and an MBA degree from Harvard Business School.
Partner at Lifeforce Capital
Sander is a Partner at Lifeforce Capital. Previously, Sander served as Vice President, Business Development for Pager, a venture-backed digital health company focused on improving patient access to the right care. Sander helped to evolve Pager’s business to a national enterprise-facing company selling to leading payers and health systems while overseeing sales, account management, strategic partnerships, and corporate development. Before Pager, Sander was a founder of Northwell Ventures, the corporate ventures arm for New York State’s largest health system, and a leader at Cleveland Clinic Ventures focused on making venture investments in outside companies and developing spin-outs based on Cleveland Clinic technology. He began his career in healthcare private equity after graduating from Dartmouth with a BA in Molecular Biology.
Founding Managing Partner, RoyaltyRx Capital
Mr. Davis is a Founding Managing Partner at RoyaltyRx Capital, a special opportunities investment firm. He previously co-founded and was Managing Partner at HealthCare Royalty Partners, a global healthcare investment firm. He has thirty years of experience working in and investing in the pharmaceutical and biotechnology industries. Over the course of his career, Mr. Davis has been involved in over $2 billion in healthcare deals and nearly $1 billion in royalty financings. He has also led, structured and closed over 40 additional intellectual property licenses, as well as growth equity, and debt deals. Previously, Mr. Davis was a partner at Paul Capital Partners, where he co-managed that firm’s royalty investments as a member of the royalty management committee. He also served as a partner responsible for biopharmaceutical growth equity investments at Apax Partners. Prior to beginning his principal investment career in 2001, Mr. Davis held sales and product management roles at Abbott Laboratories and was in business development, operations and licensing at Elan Pharmaceuticals. Mr. Davis holds a B.S. from the U.S. Naval Academy and an M.B.A. from Harvard University. He currently serves on the board of Ligand Pharmaceuticals (NASDAQ: LGND), BioDelivery Sciences Inc. (NASDAQ: BDSI), and Palvella Therapeutics, a private biopharmaceutical company he seeded that is committed to serving patients with debilitating rare, genetic diseases through the development and commercialization of life-changing, pathogenetically targeted therapies.
Brenton Fargnoli, MD is a Partner at AlleyCorp, where he leads the firm’s early-stage healthcare investments and incubations. Prior to AlleyCorp, Brenton was an executive at Flatiron Health, where he started Flatiron’s value-based care initiative and scaled it nationally, built-out and oversaw Product Marketing and Strategy, and was instrumental in the partnership with OneOncology which launched with $200M in funding. He is also a practicing physician, board certified in Internal Medicine.
Brenton completed his residency at Harvard’s Brigham and Women’s Hospital. He graduated summa cum laude from the University of Pennsylvania, earning his MD from the University of Pennsylvania School of Medicine and an MBA in Healthcare Management from the Wharton School.
Windham Venture Partners General Partner & CEO
Adam Fine is a co-founder and CEO of Windham Venture Partners. Adam is currently Director at Coravin, GlySens, CuraSeal and HelpAround, Board Observer to SpineView, MC10, Holaira and VytronUS. Adam is a mentor in Blueprint Health, a healthcare IT accelerator in NYC. Prior to Windham, Adam was VP & GM at I-many, Inc., an enterprise software company. Prior to joining I-many, Adam was a New Business Development Analyst at Cordis Corporation, a Johnson & Johnson company focused on interventional vascular devices such as stents. In that capacity, Adam worked on a range of licenses, acquisitions, divestments, as well as strategic investments with Johnson & Johnson Development Corporation (JJDC), J&J’s strategic venture arm. Prior to J&J, Adam was a research analyst at Coopers & Lybrand’s Integrated Healthcare Consulting practice.
Adam received his BA and graduated cum laude with distinction from Boston University and received his MBA from New York University.
Barbara Schilberg has held multiple leadership positions in the life sciences sector for over 30 years. Since 2002 she has served as the CEO of BioAdvance, an investor in early-stage life sciences companies and technologies in the mid-Atlantic region, growing the evergreen fund from $20M to $50M. During her tenure BioAdvance has invested $45 million in 90 companies and academic technologies, which have attracted $2.76 billion in capital; twelve companies have been acquired and eleven products have been approved by the FDA. Before joining BioAdvance Barbara served in senior management of Cephalon and three other biotech companies, where she was responsible for programs ranging from discovery to Phase 3 clinical studies. Before joining the biopharma industry, she represented a variety of universities and biotech companies with financings and technology commercialization as a partner at Morgan Lewis.
1221 Ave Of The Americas, New York, NY, 10020